Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.07
AKRX's Cash to Debt is ranked lower than
95% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AKRX: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
AKRX' s 10-Year Cash to Debt Range
Min: 0  Med: 0.28 Max: N/A
Current: 0.07
Equity to Asset 0.20
AKRX's Equity to Asset is ranked lower than
92% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AKRX: 0.20 )
Ranked among companies with meaningful Equity to Asset only.
AKRX' s 10-Year Equity to Asset Range
Min: 0.18  Med: 0.54 Max: 0.86
Current: 0.2
0.18
0.86
F-Score: 4
Z-Score: 2.75
M-Score: -0.92
WACC vs ROIC
10.62%
6.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.31
AKRX's Operating margin (%) is ranked higher than
75% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. AKRX: 16.31 )
Ranked among companies with meaningful Operating margin (%) only.
AKRX' s 10-Year Operating margin (%) Range
Min: -50.73  Med: -0.73 Max: 27.76
Current: 16.31
-50.73
27.76
Net-margin (%) 5.96
AKRX's Net-margin (%) is ranked higher than
50% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. AKRX: 5.96 )
Ranked among companies with meaningful Net-margin (%) only.
AKRX' s 10-Year Net-margin (%) Range
Min: -36.46  Med: -3.65 Max: 31.41
Current: 5.96
-36.46
31.41
ROE (%) 11.59
AKRX's ROE (%) is ranked higher than
64% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. AKRX: 11.59 )
Ranked among companies with meaningful ROE (%) only.
AKRX' s 10-Year ROE (%) Range
Min: -127.6  Med: -9.58 Max: 35.12
Current: 11.59
-127.6
35.12
ROA (%) 3.00
AKRX's ROA (%) is ranked higher than
50% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AKRX: 3.00 )
Ranked among companies with meaningful ROA (%) only.
AKRX' s 10-Year ROA (%) Range
Min: -33.5  Med: -3.83 Max: 24.27
Current: 3
-33.5
24.27
ROC (Joel Greenblatt) (%) 31.70
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. AKRX: 31.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -48.35  Med: 0.07 Max: 69.84
Current: 31.7
-48.35
69.84
Revenue Growth (3Y)(%) 54.00
AKRX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AKRX: 54.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AKRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37  Med: -0.05 Max: 54
Current: 54
-37
54
EBITDA Growth (3Y)(%) 37.00
AKRX's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AKRX: 37.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AKRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.1  Med: 41.50 Max: 171.4
Current: 37
-67.1
171.4
EPS Growth (3Y)(%) -6.00
AKRX's EPS Growth (3Y)(%) is ranked lower than
65% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AKRX: -6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AKRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4  Med: 10.95 Max: 93.1
Current: -6
-50.4
93.1
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AKRX Guru Trades in Q2 2014

Columbia Wanger 8,123,700 sh (+12.58%)
Jim Simons Sold Out
Pioneer Investments 254,698 sh (-14.49%)
Murray Stahl 26,464 sh (-24.76%)
Mario Gabelli 9,950 sh (-37.42%)
Joel Greenblatt 39,285 sh (-42.33%)
» More
Q3 2014

AKRX Guru Trades in Q3 2014

Paul Tudor Jones 14,400 sh (New)
Steven Cohen 49,100 sh (New)
Pioneer Investments 213,151 sh (unchged)
Mario Gabelli 9,300 sh (-6.53%)
Murray Stahl 23,011 sh (-13.05%)
Columbia Wanger 6,846,275 sh (-15.72%)
Joel Greenblatt 24,479 sh (-37.69%)
» More
Q4 2014

AKRX Guru Trades in Q4 2014

Steven Cohen 121,600 sh (+147.66%)
Joel Greenblatt 26,536 sh (+8.40%)
Pioneer Investments Sold Out
Paul Tudor Jones 14,300 sh (-0.69%)
Murray Stahl 22,606 sh (-1.76%)
Columbia Wanger 6,524,486 sh (-4.70%)
Mario Gabelli 7,500 sh (-19.35%)
» More
Q1 2015

AKRX Guru Trades in Q1 2015

George Soros 15,500 sh (New)
Louis Moore Bacon 70,000 sh (New)
Paul Tudor Jones 27,977 sh (+95.64%)
Mario Gabelli 13,000 sh (+73.33%)
Steven Cohen 196,200 sh (+61.35%)
Joel Greenblatt 35,233 sh (+32.77%)
Murray Stahl 17,721 sh (-21.61%)
Columbia Wanger 4,209,486 sh (-35.48%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 190.26
AKRX's P/E(ttm) is ranked lower than
92% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. AKRX: 190.26 )
Ranked among companies with meaningful P/E(ttm) only.
AKRX' s 10-Year P/E(ttm) Range
Min: 13.23  Med: 43.61 Max: 337.5
Current: 190.26
13.23
337.5
Forward P/E 19.61
AKRX's Forward P/E is ranked higher than
63% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. AKRX: 19.61 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 181.60
AKRX's PE(NRI) is ranked lower than
92% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. AKRX: 181.60 )
Ranked among companies with meaningful PE(NRI) only.
AKRX' s 10-Year PE(NRI) Range
Min: 13.17  Med: 44.03 Max: 318.21
Current: 181.6
13.17
318.21
P/B 12.70
AKRX's P/B is ranked lower than
92% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. AKRX: 12.70 )
Ranked among companies with meaningful P/B only.
AKRX' s 10-Year P/B Range
Min: 1.42  Med: 6.93 Max: 41.45
Current: 12.7
1.42
41.45
P/S 9.64
AKRX's P/S is ranked lower than
78% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. AKRX: 9.64 )
Ranked among companies with meaningful P/S only.
AKRX' s 10-Year P/S Range
Min: 0.76  Med: 6.18 Max: 12.87
Current: 9.64
0.76
12.87
POCF 190.30
AKRX's POCF is ranked lower than
95% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. AKRX: 190.30 )
Ranked among companies with meaningful POCF only.
AKRX' s 10-Year POCF Range
Min: 23.75  Med: 52.33 Max: 230.17
Current: 190.3
23.75
230.17
EV-to-EBIT 68.86
AKRX's EV-to-EBIT is ranked lower than
82% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. AKRX: 68.86 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s 10-Year EV-to-EBIT Range
Min: -430.4  Med: -7.90 Max: 114.3
Current: 68.86
-430.4
114.3
Shiller P/E 205.29
AKRX's Shiller P/E is ranked lower than
93% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. AKRX: 205.29 )
Ranked among companies with meaningful Shiller P/E only.
AKRX' s 10-Year Shiller P/E Range
Min: 110.53  Med: 181.63 Max: 728
Current: 205.29
110.53
728
Current Ratio 3.68
AKRX's Current Ratio is ranked higher than
68% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. AKRX: 3.68 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s 10-Year Current Ratio Range
Min: 0.3  Med: 2.22 Max: 5.51
Current: 3.68
0.3
5.51
Quick Ratio 2.71
AKRX's Quick Ratio is ranked higher than
67% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. AKRX: 2.71 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s 10-Year Quick Ratio Range
Min: 0.06  Med: 1.04 Max: 4.26
Current: 2.71
0.06
4.26
Days Inventory 121.31
AKRX's Days Inventory is ranked lower than
54% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. AKRX: 121.31 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s 10-Year Days Inventory Range
Min: 42.24  Med: 133.25 Max: 188.37
Current: 121.31
42.24
188.37
Days Sales Outstanding 135.84
AKRX's Days Sales Outstanding is ranked lower than
83% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. AKRX: 135.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s 10-Year Days Sales Outstanding Range
Min: 10.09  Med: 47.50 Max: 135.84
Current: 135.84
10.09
135.84

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 14.07
AKRX's Price/Projected FCF is ranked lower than
88% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. AKRX: 14.07 )
Ranked among companies with meaningful Price/Projected FCF only.
AKRX' s 10-Year Price/Projected FCF Range
Min: 8.35  Med: 13.23 Max: 50.58
Current: 14.07
8.35
50.58
Price/Median PS Value 1.53
AKRX's Price/Median PS Value is ranked lower than
55% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. AKRX: 1.53 )
Ranked among companies with meaningful Price/Median PS Value only.
AKRX' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.35 Max: 1.95
Current: 1.53
0.08
1.95
Earnings Yield (Greenblatt) (%) 1.49
AKRX's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AKRX: 1.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.9  Med: 2.75 Max: 5.3
Current: 1.49
0.9
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FDA.Germany,
Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the products market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 
Weekly CFO Buy Highlights: Gigatronics Inc., Akorn Inc., MainSource Financial Group Inc, U.S. Auto P Sep 06 2009 

More From Other Websites
The Law Firm of Morgan & Morgan Is Investigating Possible Breaches of Fiduciary Duty At Akorn Inc.... Jul 29 2015
Analysts expect more tie-ups in generic drug business Jul 27 2015
Analysts expect more tie-ups in generic drug business Jul 27 2015
5 Mid-Caps With Unsustainable Cash Burn Rates Jul 27 2015
Pharma Pair Trade? Susquehanna Starts Lannet At Buy, Akorn At Neutral Jul 21 2015
Coverage initiated on Akorn by Susquehanna Jul 21 2015
Akorn Announces Nasdaq's Acceptance of Its Plan to Regain Compliance Jul 15 2015
AKORN INC Files SEC form 8-K, Other Events Jul 15 2015
Akorn Announces Nasdaq's Acceptance of Its Plan to Regain Compliance Jul 15 2015
Akorn Launches Acetylcysteine Injection Jul 14 2015
4 Specialty Pharmaceutical Stocks Could Be the Next Takeover Candidates Jul 10 2015
Rate Hikes Won't Kill Pharma M&A Boom…and These Stocks Could Be Next Jul 08 2015
Akorn Launches Acetylcysteine Injection Jul 08 2015
Inspire Pharma – with deep Triangle roots – settles civil fraud claim Jun 18 2015
View And Use EPS, RS Ratings Through Prism Of The Market Jun 05 2015
Wall Street expects these health-care stocks to rise up to 55% May 29 2015
Who's The Next Big Pharma Acquisition? May 29 2015
AKORN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... May 20 2015
Celgene, Lannett Lead Boisterous Day For Drugmakers May 18 2015
AKORN INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK